Biphasic Temporal Remodeling Of The Proteome In A Polyglutamine-Expanded Huntingtin In Vitro Aggregation Cell Model: From Early Rna-Regulatory Compensation To Selective Mitochondrial Energy Failure

Huntington disease, brought on by a gene mutation resulting in an expanded polyglutamine protein, leads to progressive cellular harm. Yet, the sequence of these harmful events - especially early, reversible changes compared to later, irreversible ones - is not yet clear due to their significant therapeutic impact. To better understand this process, researchers studied a cell line with the huntingtin gene and observed changes in its protein makeup at two key time points: 72 hours and 144 hours.

Initially, rather than a straightforward progression towards disease, the cellular response seemed to unfold in two separate phases. During the early stage, the cells showed a wide-ranging activation of their DNA processing, splicing, and protein creation mechanisms. This was likely a defensive reaction to manage stress. However, by the later stage, this protective mechanism seemed to have failed, leading to a major breakdown in the cell's ability to produce energy through its mitochondria.

Interestingly, about 85% of the proteins that changed at both time points actually reversed their alteration between the two stages. This suggests that the mutated huntingtin protein fundamentally reprograms the cell's functions rather than simply amplifying existing issues. Further investigation into the mitochondria's energy-producing machinery showed that elements critical for generating ATP, like cytochrome c oxidase and ATP synthase, were severely damaged.

Conversely, earlier steps in the electron transport process remained functional or even increased in activity.

Using this detailed map of changes in cellular proteins, a computer-assisted drug screening method was employed. Out of 1,712 proteins that showed altered expression, 498 were potentially treatable with existing medications. Among these, 89 could be linked to currently approved drugs whose mechanisms support the needed cellular correction.

Notably, these included treatments targeting the first mitochondrial complex (metformin, ME 344) and compounds that support mitochondrial health (SS 31, MitoQ). Several of these treatments have already been explored in research related to Huntington disease.

Overall, this study clarifies the two-stage pattern of harm caused by the mutated huntingtin protein. It also indicates a critical window of opportunity early in the disease process where intervention may be most effective, before the cell's mitochondrial energy production is irreversibly damaged.